Biem is a biotechnology-focused pharmaceutical company founded in 1991 by Pharmacist Levent Canyurt established with domestic capital. The company began its journey by introducing innovative therapies to the Turkish pharmaceutical and healthcare market, quickly establishing a strong presence within the industry. Biem subsequently became the exclusive Turkish distributor for leading pharmaceutical companies based in the United States and Europe, with a particular focus on highly specialized therapeutic areas such as plasma-derived medicinal products. This foundation enabled the company to build a strong and reputable corporate position.
Today, Biem develops and manufactures products protected by intellectual property rights through a local manufacturing infrastructure that fully complies with global regulatory and licensing requirements. Supported by a strong R&D organization and an advanced manufacturing facility, the company manages the highly specialized processes required for biological pharmaceuticals within integrated quality management systems.
Biem operates across a broad range of specialized therapeutic areas, including oncology, hematology, radiology, ophthalmology, neurology, intensive care, nephrology, gastroenterology, and transplantation. Backed by decades of experience, internationally aligned quality standards, and robust scientific and operational capabilities, Biem has established itself as a respected and trusted partner in the pharmaceutical industry.
Our Mission is…
To become the FIRST REMEDY for improving the quality of life with innovative products and saving lives through a high-quality service principle; and to become the ONLY REMEDY by offering state-of-the-art medicines to patients without pursuing high profit margins for the treatment of diseases that affect only a few people worldwide.
Our Vision is…
To achieve sustainable growth across our therapeutic areas through innovation and scientific excellence; to continuously enhance the quality of healthcare by delivering safe, effective, and high-quality pharmaceutical products; and to uphold the highest ethical standards in all our activities while developing innovative solutions that contribute to healthier and happier lives.
Milestones
1991
Establishment
Biem becomes exclusive distributer of Cutter USA and becomes a limited company within the year.
2011
Distributer
Until 2011 Biem was distributer of Export volume increased
Cutter & Miles / Bayer / Talecris
2012-14
CT, MR Contrast and Oncology-Hematology
Launch of CT, MR Contrast and Oncology-Hematology Portfolio
2015
New Launches
Launch of Intensive Care product portfolio
2019
R&D Labratory Establishment
Biem established its R&D laboratory at MARTEK, Gebze, Kocaeli in 2019.
2022
Export Milestone
Export volume increased to 32 countries.
2024
Factory
Completed construction of the manufacturing site (30.000 m² closed area)
2024
Initial Public Offering
Biem received the preliminary approval for its initial
public offering (IPO), stepping into a new phase in investment
2025
Manufacturing Facility Started to Operate
The Turkish GMP certification was obtained, and the European GMP inspection was performed. The Biem Manufacturing Facility began manufacturing its products and exporting them to international markets.
2026
Globaly Recognised Company
Biem gathered 80+ MA approvals in more than 40 countries.